Regeneron Pharmaceuticals, Inc.

Other

University of Texas System

Univ. of Texas

Nikos Panayotatos

George D Yancopoulos

Melanie H Cobb

Teri G Boulton

Steven Nye

James P Fandl

Stanley J Wiegand

Mark E Furth

Friedrich Lottspeich

Vivien Wong

Nancy Y Ip

Hans Thoenen

Ronald M Lindsay

Piotr J Masiakowski

Patrick Desmond Carroll

Keith D Anderson

Yoshihiro Arakawa

Kurt Stockli-Rippstein

Michael Sendtner

Georg W Kreutzberg

Rudolf Georg Gotz

Dan B Lindholm

DNA encoding human ciliary neurotrophic factor and method for producing the protein encoded thereby

Modified ciliary neurotrophic factors and methods for their production and therapeutic use. Also described is a method of screening for novel therapeutic proteins by determining altered electrophoretic binding properties.

Nucleic acids encoding modified ciliary neurotrophic factors

Modified ciliary neurotrophic factors and methods for their production and therapeutic use, especially in the treatment of Huntington's disease.

Administration modified ciliary neurotrophic factors

The present invention relates to complexes between (1) a target-binding moiety; (2) a cavity-forming moiety; and (3) a pharmacological compound to be delivered to a target, wherein the pharmacological compound is buried inside of the cavity-forming moiety, but not covalently bound to either the target-binding moiety or the cavity-forming moiety. The complexes of thus invention may be used as to deliver a pharmacological compound to cells, tissues, organs, viruses, microorganisms or other surfaces that are characterized by an entity that binds the target-binding moiety portion of the complex. The present invention also relates to pharmaceutical compositions comprising the non-covalent complexes of this invention. The invention also relates to methods of delivering a pharmacological compound to a target in a patient. The present invention also relates to the use of the complexes of this invention for the separation of chemical entities from their chiral forms or contaminants.

Protein occlusion for delivery of small molecules

The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity. These methods may be extremely useful in screening compounds for the presence of a desired cellular factor activity. In specific embodiments, compounds which may be useful in the treatment of Alzheimer's disease, peripheral neuropathies, and diabetes may be identified using the methods of the invention.

ERK3 MAP2 protein kinase

ERK1 MAP2 protein kinase

Antibodies directed toward extracellular signal-related kinases

Family of MAP2 protein kinases

Modified ciliary neurotrophic factors

The present invention relates to expression of recombinant proteins by use of a bacterial host expression vector which expresses a recombinant protein under the control of a first regulatory expression element, and expresses a selectable marker under the control of a second regulatory expression element, which second element is mutated such that expression of the selectable marker is at reduced levels relative to that directed by such an unmutated expression element. Such an expression vector in a suitable bacterial host (a) allows ease of purification of the recombinant protein of interest ('the recombinant protein') since less selectable marker is present to interfere with the purification of the recombinant protein, and (b) increases the amount of recombinant protein that is produced by the bacterial host cell. Furthermore, in an embodiment in which the selectable marker is an antibiotic resistance gene, expression according to the present invention ensures that only the minimal necessary levels of antibiotic will be used for selection during fermentation. The invention provides expression vectors, host-vector expression systems (comprising the expression vector in a bacterial host in which it can be expressed), and methods relating thereto.

Recombinant protein production with reduced expression of selectable

Family of map2 protein kinases

Signal sequences based on LamB have been constructed. These signal sequences facilitate both the synthesis and secretion of neurotrophins in E. coli.

Modified lam.beta. signal sequence and processes for producing

Growing community of inventors

Orangeburg, NY, United States of America

Nikos Panayotatos